1. CORESTA Meeting, Agronomy/Phytopathology, 2019, Victoria Falls, AP Sustainability Forum

    Agro-Phyto Sustainability Forum

    WILDE L.(1); PRIBIC V.(2); EVANS W.(3); ROYO E.(4); BARGIACCHI E.(5); COLARD S.(6)
    (1) twentyfifty Ltd, Frome, U.K.; (2) JT International S.A., Geneva, Switzerland; (3) Imperial Tobacco Limited, Durban, South Africa; (4) Philip Morris International, Cape Town, South Africa; (5) Consortium INSTM, Firenze, Italy; (6) CORESTA, Paris, France
    In 2015, the United Nations published 17 sustainable development goals and their corresponding targets to be achieved by 2030. Like other sectors, the tobacco and alternative product sectors are likely to impact most of the goals. Consequently, it is ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 09

    The ABOUT™ Toolbox: toward the development of consumer-reported outcome measures that matter

    CHREA C.(1); SPIES E.(1); AFOLALU E.(1); BACSO A.(1); CLERC E.(1); MAINY N.(1); BINGGELI P.(1); WEITKUNAT R.(1); ACQUADRO C.(2); SALZBERGER T.(3); CANO S.(4); ABETZ-WEBB L.(5); ROSE J.(6)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Mapi, an ICON plc Company, Lyon, France; (3) University of Economics and Business, Vienna, Austria; (4) ScaleReport, Ltd, Stotfold, U.K.; (5) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (6) Rose Research Center, Raleigh, U.S.A.
    Tobacco harm reduction promotes the substitution of reduced-risk products (RRPs) for cigarettes by adult smokers who would otherwise continue to smoke, while preventing RRP initiation among non-users. To operationalize this public health strategy, there ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 10

    Development of the ABOUT™–Health & Functioning: results from the preparatory phase

    SPIES E.(1); BACSO A.(1); CHREA C.(1); ABETZ-WEBB L.(2); AFOLALU E.(1); CLERC E.(1); WEITKUNAT R.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.
    Switching cigarette smokers to significantly less harmful tobacco or nicotine products, or reduced-risk products (RRPs), has been recognized as a valuable and promising approach to reduce smoking-related population harm. Measuring self-reported experience ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 11

    Development and validation of the ABOUT™–Dependence measurement instrument to assess perceived dependence on tobacco and nicotine products

    AFOLALU E.(1); CHREA C.(1); SALZBERGER T.(2); ABETZ-WEBB L.(3); CANO S.(4); WEITKUNAT R.(1); ROSE J.(5)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) University of Economics and Business, Vienna, Austria; (3) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (4) Modus Outcomes, Letchworth Garden City, U.K.; (5) Rose Research Center, Raleigh, U.S.A.
    The development of the ABOUT™–Dependence measurement instrument was initiated to enable assessment of perceived dependence associated with the use of different tobacco and nicotine products (TNPs) and in users of multiple TNPs. We initially developed a ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 12

    Review of current methodologies in evaluating abuse liability of nicotine and tobacco products in the U.S. regulatory environment

    EVANS S.(1); KONG M.C.(2); CAMPBELL L.(2); SHERWOOD N.(3); PRASAD K.(4)
    (1) Turning Point Brands, Louisville, KY, U.S.A.; (2) Altasciences Clinical Research, Laval, Canada; (3) Neil Sherwood Consulting, Nyon, Switzerland; (4) British American Tobacco, R&D, Millbrook, Southampton, U.K.
    Traditional definitions of abuse and misuse do not apply to a consumer product such as tobacco that consumers essentially use ‘as intended’. In contrast to pharmaceutical products, a guidance for abuse liability testing of nicotine and tobacco products ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 23 (also presented at TSRC 2019)

    Functional filter plug wrap paper for control of the thermal energy of the aerosol from heated tobacco products (HTPs)

    LINDNER M.; LEICHSENRING N.
    (1) TANNPAPIER GmbH, Traun, Austria; (2) Hauni Maschinenbau GmbH, Hamburg, Germany
    Next generation products, which include all kinds of e-vapour items as well as heated tobacco products (HTPs or “heat sticks”), have successfully entered the tobacco market in addition to conventionally combustible cigarettes. From the basic geometrical ...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 29

    Thermochemical and thermophysical mapping of burning superslim and kingsize cigarettes

    EHLERT S.(1,3); CUI H.(2); HEIDE J.(3); XIE F.(2); DENG N.(2); LIU C.(4); McADAM K.(4); WALTE A.(1); ZIMMERMANN R.(3)
    (1) Photonion GmbH, Schwerin, Germany; (2) Zhengzhou Tobacco Research Institute of CNTC, Zhengzhou, Henan, P.R. China; (3) University of Rostock, Dept. of Analytical Chemistry, Rostock, Germany; (4) British American Tobacco, R&D Centre, Southampton, U.K.
    After presenting and publishing the proof of principle of the in-situ thermochemical and thermophysical mapping inside a burning Super Slim (SS) cigarette, we now extended the study scope to other cigarette formats and smoking regimes [1]. A Chinese ...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 44

    Lung biomarkers of harm/effect for tobacco regulatory research: opportunities and challenges – a literature review

    MAKENA P.(1); EDMISTON J.(2); BEATTIE E.(3); MASON E.(4); McEWAN M.(5); PRASAD K.(5)
    (1) RAI Services Company, Winston-Salem, NC, U.S.A.; (2) Altria Client Services LLC, Richmond, VA, U.S.A.; (3) Cliantha Research Limited, Canada; (4) Imperial Brands PLC, Bristol, U.K.; (5) British American Tobacco (Investments) Limited, Southampton, U.K.
    Biomarkers of potential harm (BoPH) are indicators of biological perturbations in response to smoking, which may contribute to smoking-related disease. In this review, a project of the CORESTA Biomarkers Sub-Group, we critically assessed the available ...